Methods to Evaluate Novel Hepatitis C Virus Vaccines.

Area of Science:

• Hepatology and Immunology
• Vaccine Development
• Virology

Background:

• Chronic Hepatitis C virus (HCV) infection affects 130-170 million globally, increasing liver disease risk.
• HCV is a silent epidemic, often diagnosed late, necessitating effective treatments.
• Current direct-acting antivirals (DAAs) are costly and inaccessible in many regions.

Purpose of the Study:

• To describe the rationale for developing highly immunogenic therapeutic vaccines for chronic HCV infection.
• To explore strategies for improving vaccine immunogenicity and methods for evaluating efficacy.
• To present a method for designing HCV vaccines and a protocol for assessing their efficacy.

Main Methods:

• Vaccine delivery via intramuscular immunization combined with in vivo electroporation/electrotransfer (EP/ET).
• Immunological analysis including interferon-γ (IFN-γ) production by ELISpot assay.
• Ex vivo quantification of HCV NS3/4A-specific CD8+ T cells using pentamer staining and in vivo bioluminescence imaging.

Main Results:

• Genetic vaccine candidates have shown limited effects on viral load and immune response activation in clinical trials.
• The described methods aim to overcome limitations of current vaccine approaches.
• Detailed protocols for vaccine design and efficacy assessment are presented.

Conclusions:

• Therapeutic vaccines are needed as an alternative or adjunct to DAAs for chronic HCV.
• Activating HCV-specific T cells is key to eradicating infected hepatocytes.
• The study provides a framework for designing and evaluating novel HCV vaccines.